Browsing by Author "Meriläinen, Eve"

The dissertation focus on new pharmaceutical Parkinson disease treatments which are in phase III and II. Most of the development projects in phase III have the same mode-of-action as the current available products, hence the only major difference is their administration routes. The aim of the different administrations routes and times is to ease patients’ daily life by making dosing more convenient and/or reducing the well-known and common adverse effects. Most of these phase III projects are not revolutionary or do not offer fair or a proper solution for unmet clinical needs which are related to current available medication. One of the phase III compounds may have potential to change the treatment of Parkinson’s disease if it manages to demonstrate its neuroprotective impact. Phase II compounds differ notably by their mode-of-actions from the current products. They also have more variable molecule type range. The most interesting treatments in phase II are concentrated on stopping or slowing down the progression of Parkinson disease with neuroprotective and neurorestorative effects. All the molecules under the development have demonstrated good safety and tolerability. However, more clinical trials and data are needed before these products can be taken onto common use. With new hypothesis about Parkinson’s disease and its offset, the future treatments may also focus on another target organs like gut bacteria in order to prevent the off set of Parkinson disease.